• 1. Kinetic resolution of amines with enantiopure 3-N,N-diacylaminoquinazolin-4(3H)-ones
  Abdullah G. Al-Sehemi,Robert S. Atkinson,John Fawcett J. Chem. Soc. Perkin Trans. 1 2002 257
• 2. Parallel kinetic resolution of racemic amines using 3-N,N-diacylaminoquinazolin-4(3H)-ones
  Abdullah G. Al-Sehemi,Robert S. Atkinson,Christopher K. Meades Chem. Commun. 2001 2684
• 3. Kinetic resolution of amines by acylation using3-diacylaminoquinazolin-4(3H)-ones
  Abdullah G. Al-Sehemi,Robert S. Atkinson,John Fawcett,David R. Russell Chem. Commun. 2000 43
• 4. Thermoresponsive polymers in non-aqueous solutions
  Matilde Concilio,Valentin P. Beyer,C. Remzi Becer Polym. Chem. 2022 13 6423
• 5. Thermoresponsive polymers in non-aqueous solutions
  Matilde Concilio,Valentin P. Beyer,C. Remzi Becer Polym. Chem. 2022 13 6423

Recent Advances in the Application of (2R)-2-methylpiperidine (CAS: 1722-95-8) in Chemical Biology and Pharmaceutical Research

The compound (2R)-2-methylpiperidine (CAS: 1722-95-8) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. As a chiral building block, it plays a crucial role in the synthesis of various bioactive molecules, including pharmaceuticals and agrochemicals. This research brief aims to summarize the latest findings and advancements related to this compound, focusing on its synthesis, biological activities, and potential therapeutic applications.

Recent studies have highlighted the importance of (2R)-2-methylpiperidine in asymmetric synthesis and drug discovery. Its stereochemical properties make it an ideal candidate for the development of enantiomerically pure compounds, which are often required for high-efficacy drugs. For instance, researchers have successfully incorporated this moiety into novel kinase inhibitors, demonstrating enhanced selectivity and reduced off-target effects. The compound's ability to modulate protein-protein interactions has also been explored, opening new avenues for targeting previously undruggable proteins.

In terms of synthetic methodologies, significant progress has been made in the efficient production of (2R)-2-methylpiperidine. A 2023 study published in the Journal of Organic Chemistry reported a novel catalytic asymmetric synthesis route that achieves high enantiomeric excess (ee > 99%) and excellent yield (92%). This breakthrough addresses previous challenges in large-scale production and paves the way for broader applications in pharmaceutical manufacturing. Additionally, green chemistry approaches utilizing biocatalysts have shown promise in reducing environmental impact while maintaining high stereoselectivity.

The pharmacological potential of (2R)-2-methylpiperidine derivatives has been extensively investigated in recent preclinical studies. Several research groups have reported promising results in central nervous system (CNS) disorders, with derivatives showing potent activity as serotonin and norepinephrine reuptake inhibitors. These findings suggest potential applications in treating depression and anxiety disorders. Furthermore, structural modifications of the (2R)-2-methylpiperidine scaffold have yielded compounds with notable antimicrobial activity against drug-resistant bacterial strains, addressing a critical need in the era of antibiotic resistance.

From a drug delivery perspective, (2R)-2-methylpiperidine has been utilized to improve the pharmacokinetic properties of therapeutic agents. Its incorporation into prodrug designs has demonstrated enhanced blood-brain barrier penetration and increased oral bioavailability. Recent work published in Molecular Pharmaceutics detailed how this approach significantly improved the therapeutic index of a novel antipsychotic candidate currently in phase II clinical trials.

Looking forward, the unique properties of (2R)-2-methylpiperidine continue to inspire innovative research directions. Computational chemistry and artificial intelligence approaches are being employed to design next-generation derivatives with optimized binding affinities and reduced toxicity profiles. The compound's versatility ensures its ongoing relevance in medicinal chemistry, with potential applications expanding into areas such as targeted cancer therapies and neurodegenerative disease treatments. As research progresses, we anticipate seeing more (2R)-2-methylpiperidine-based candidates advancing through clinical development pipelines.

• 282-57-5(10-Azabicyclo[4.3.1]decane)
• 35285-25-7(Solenopsin A)
• 72939-22-1(2-butylpiperidine)
• 22160-08-3((R)-2-Ethylpiperidine)
• 280-97-7(9-azabicyclo3.3.1nonane)
• 35285-26-8(Piperidine,2-methyl-6-tridecyl-, (2R,6S)-rel-)
• 88982-00-7(Piperidine, 2,6-diethyl-, trans-)
• 458-88-8(Piperidine, 2-propyl-,(2S)-)
• 65266-41-3(Piperidine, 2-methyl-6-propyl-, (2R,6S)-)
• 5985-99-9(Piperidine, 2-propyl-, (2R)-)